Inhibrx Biosciences Inc. (INBX) — AI News Sentiment & Analysis

Primary endpoint results from the randomized and controlled Phase 2 HexAgon study of INBRX-106 plus pembrolizumab. (Timing: Phase 2 trial expansion by approximately 50 additional HPV+ patients and future alignment with the FDA.)

Upcoming clinical data readouts and regulatory milestones, including ozekibart PDUFA date in April 2027. (Timing: Q3 2026 to Q1 2027)

FDA acceptance of the Biologics License Application (BLA) for ozekibart, moving the drug closer to potential market approval. (Timing: PDUFA goal date of April 14, 2027.)

Positive interim Phase 2 clinical results for INBRX-106 in first-line HNSCC, demonstrating a significant improvement in objective response rate and manageable safety profile. (Timing: Next data on progression-free survival expected Q4 2026; Phase 3 study initiation planned for Q3 2026.)

Positive interim Phase 1/2 clinical data for Ozekibart in colorectal cancer, combined with a Biologics License Application (BLA) submission to the FDA for Ozekibart in chondrosarcoma. Planned FDA meetings in H2 2026 for registrational trials and accelerated pathways are also future catalysts. (Timing: Immediate for the data and BLA submission; H2 2026 for FDA meetings and potential trial initiations.)

The reported full-year losses and the new $75 million debt facility are immediate negative catalysts, as they highlight significant financial hurdles for the company. (Timing: Immediate impact, following the earnings release and market reaction.)